Stock TRML TOURMALINE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
15.68 USD -2.00% Intraday chart for Tourmaline Bio, Inc. +1.49% -40.11%
04-25 Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
04-25 Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Certain Common Stock of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.
CI
Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected
MT
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady
MT
Top Premarket Decliners
MT
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027
MT
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024
CI
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing
MT
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GL
Tourmaline Bio Prices $150 Million Common Stock Offering
MT
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
GL
Tourmaline Bio Announces Proposed Public Offering of Common Stock
GL
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
GL
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index
CI
Tourmaline Bio Joins Nasdaq Biotechnology Index
MT
Tourmaline Bio added to the NASDAQ Biotechnology Index
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRML Stock
  4. News Tourmaline Bio, Inc.